Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
GlaxoSmithKline
Pharmacyclics LLC.
Fate Therapeutics
Swiss Cancer Institute
Masonic Cancer Center, University of Minnesota
Fox Chase Cancer Center
US Oncology Research
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)